RT Journal Article
SR Electronic
T1 Mitigating COVID-19 outbreak via high testing capacity and strong transmission-intervention in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.03.20052720
DO 10.1101/2020.04.03.20052720
A1 Chen, Shi
A1 Li, Qin
A1 Gao, Song
A1 Kang, Yuhao
A1 Shi, Xun
YR 2020
UL http://medrxiv.org/content/early/2020/04/07/2020.04.03.20052720.abstract
AB Most models of the COVID-19 pandemic in the United States do not consider geographic variation, and their relevance to public policies is not straightforward. We developed a mathematical model that characterizes infections by state and incorporates inflows and outflows of interstate travelers. Modeling reveals that curbing interstate travel when the disease is already widespread will make little difference. Meanwhile, increased testing capacity (facilitating early identification of infected people and quick isolation) and strict social-distancing and self-quarantine rules are effective in abating the outbreak. The modeling has also produced state-specific information. For example, for New York and Michigan, isolation of persons exposed to the virus needs to be imposed within 2 days to prevent a broad outbreak, whereas for other states this period can be 3.6 days. This model could be used to determine resources needed before safely lifting state policies on social distancing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementS.G. and Q.L. acknowledge the funding support provided by the National Science Foundation (Award No. BCS-2027375). Q.L. and S.C. acknowledge the Data Science Initiative of UW-Madison. X.S. acknowledges the Scholarly Innovation and Advancement Awards of Dartmouth College. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe infection data from an open source project: Novel Coronavirus (COVID-19) Cases, developed by the Center For Systems Science and Engineering at the Johns Hopkins University. In addition, we collected over 3.6 million points of interest (POIs) with travel patterns in the United States from the SafeGraph business venue database. https://github.com/CSSEGISandData/COVID-19/blob/master/csse_covid_19_data/csse_covid_19_time_series/time_series_covid19_confirmed_global.csv